Public-registry site landscape for NCT04797104, “Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction”, a Heterozygous Familial Hypercholesterolemia study sponsored by LIB Therapeutics LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04797104 (registry record) |
| Study title | Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction |
| Sponsor | LIB Therapeutics LLC |
| Condition(s) | Heterozygous Familial Hypercholesterolemia |
| Phase | PHASE3 |
| Listed sites | 7 |
| Intervention(s) | lerodalcibep |
| Site countries | United States, Israel, Norway, South Africa, Turkey (Türkiye) |
Patient-friendly overview of this study: eichor.com/study/NCT04797104.
Eichor generates a preliminary site-risk snapshot for NCT04797104 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
